Fatal outcome of pyoderma gangrenosum with multiple organ involvement and partially responding to Infliximab

Stefan Drinda 1 , Peter Oelzner 1 , Carolina Codina Canet 2 , Martin Kaatz 3 , Gunter Wolf 1 , and Gert Hein 1
  • 1 Department of Internal Medicine III, Friedrich Schiller University Jena, D 07740, Jena, Germany
  • 2 Department of Pathology, Friedrich Schiller University Jena, D 07740, Jena, Germany
  • 3 Department of Dermatology, Friedrich Schiller University Jena, D 07743, Jena, Germany


Pyoderma gangrenosum is an inflammatory dermatosis of uncertain etiology, often associated with chronic inflammatory bowel or rheumatoid disease. It predominantly affects the skin. A systemic organ involvement caused by aseptic neutrophilic abscesses, however, fundamentally influences the prognosis.

A patient with idiopathic pyoderma gangrenosum insufficiently responded to a conventional immune suppressive therapy and the disease proceeded aggressively. During treatment with Infliximab, partial remission was achieved intermediately. However, a recurring endocarditis, led to a lethal outcome of this patient.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • [1] P. von den Driesch: “Pyoderma gangrenosum: a report of 44 cases with follow-up”, Br. J. Dermatol., Vol. 137, (1997), pp. 1000–1005. http://dx.doi.org/10.1046/j.1365-2133.1997.20022083.x

  • [2] I. Riahi, M. Mokni, S. Haouet et al.: “Pyoderma gangrenosum. 15 cases”, Ann. Med. Interne., Vol. 152, (2001), pp. 3–9.

  • [3] M. Vadillo, A. Jucgla, D. Podzamczer et al.: “Pyoderma gangrenosum with liver, spleen and bone involvement in a patient with chronic myelomonocytic leukaemia”, Br. J. Dermatol., Vol. 141, (1999), pp. 541–543. http://dx.doi.org/10.1046/j.1365-2133.1999.03055.x

  • [4] E. Miserocchi, G. Modorati, C.S. Foster et al.: “Ocular and extracutaneous involvement in pyoderma gangrenosum”, Ophthalmology, Vol. 109, (2002), pp. 1941–1943. http://dx.doi.org/10.1016/S0161-6420(02)01165-X

  • [5] V.G. Hubbard, A.C. Friedmann and P. Goldsmith: “Systemic pyoderma gangrenosum responding to infliximab and adalimumab”, Br. J. Dermatol., Vol. 152, (2005), pp. 1059–1061. http://dx.doi.org/10.1111/j.1365-2133.2005.06467.x

  • [6] G. Koester, A. Tarnower, D. Levisohn et al.: “Bullous pyoderma gangrenosum”, J. Am. Acad. Dermatol., Vol. 29, (1993), pp. 875–878. http://dx.doi.org/10.1016/0190-9622(93)70261-Q

  • [7] A. Hernandez-Martin, D. Arias-Palomo, G. Hermida et al.: “Oral pyoderma gangrenosum” Br. J. Dermatol., Vol. 149, (2003), pp. 663–664. http://dx.doi.org/10.1046/j.1365-2133.2003.05503.x

  • [8] K.S. Kennedy, M.L. Prendergast and C.D. Sooy: “Pyoderma gangrenosum of the oral cavity, nose, and larynx”, Otolaryngol. Head Neck Surg., Vol. 97, (1987), pp. 487–490.

  • [9] M.H. Tan, M. Gordon, O. Lebwohl et al.: “Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody”, Arch. Dermatol., Vol. 137, (2001), pp. 930–933.

  • [10] M. Regueiro, J. Valentine, S. Plevy et al.: “Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease”, Am. J. Gastroenterol., Vol. 98, (2003), pp. 1821–1826. http://dx.doi.org/10.1111/j.1572-0241.2003.07581.x


Journal + Issues